GENBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Generate Biomedicines, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$12.56+0.47 (+3.89%)
Close on Oct 19, 2026
- Market cap
- $1.61B
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 6, 2026 | Before market open | $6.30M | $-0.52 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 7, 2026 | Before market open | $7.20M | – | – |
Press releases
Announcements Generate Biomedicines filed with the SEC
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Generate Biomedicines Inc. Reports Second Quarter 2026 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Reports First Quarter 2026 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K